Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. For more information, visit www.mymd.com.
The Joint Blog
JULY 25, 2020
Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. CBD is everywhere these days. Do a quick Google search, and you’ll find thousands of websites selling CBD products online , as well as the locations of brick and mortar CBD stores near you.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
Cannabis Law Report
JANUARY 5, 2022
3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. MyMD also holds three patents for its synthetic cannabidiol (CBD) derivative Supera-CBD.
SMPL
MAY 26, 2020
They sat in a circle at a house in the hills a few hours north of San Francisco — where wine country becomes weed country — to discuss the therapeutic potential of CBD, and how to get people to take it seriously. Finally, there was Fred Gardner, a writer who had recruited almost all of these people to the CBD cause.
SpeedWeed
MARCH 19, 2021
Regular doses of CBD could help prevent cognitive decline in Alzheimer’s patients, according to a new study recently published in the Journal of Alzheimer’s Disease. Over the course of two weeks, researchers gave daily doses of CBD to mice suffering from FAD. View original article.
Cannabis Law Report
MAY 19, 2019
Cannabis plant or its resin or extract with THC content lower than 1% is considered as CBD (medical) cannabis and not psychoactive. billion dollars by 2025. Underlining supplied for emphasis). Economic benefits of Marijuana: Thailand as a Case Study. Thailand’s cannabis is one of the country’s largest exports.
Expert insights. Personalized for you.
52 
Let's personalize your content